RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure

European medical technology companies remain largely insulated from Middle East geopolitical tensions and rising energy costs, according to a recent RBC Capital Markets analysis. The investment bank found that sales exposure to the Middle East ranges between 1% and 3% across the sector, while both energy and freight costs each represent a similarly modest 1% to 3% of sales and cost of goods sold, respectively.

RBC analysts Jack Reynolds-Clark, Natalia Webster, and Charles Weston assessed major players including Alcon, Carl Zeiss Meditec, Coloplast, ConvaTec, Demant, GN Store Nord, Philips, Siemens Healthineers, Smith & Nephew, Sonova, and Amplifon. Although oil is a component in many raw materials used by these companies, the bank emphasized that extensive processing layers significantly dilute oil price volatility's impact on production costs.

Hedging strategies are also helping cushion potential risks. Coloplast has hedged most of its roughly 2% energy-to-COGS exposure through 2025/26, while GN Store Nord has substantially hedged its freight costs, estimated in the low single digits as a percentage of sales. ConvaTec's energy exposure sits between 2% and 3% of cost of goods sold.

Among the companies reviewed, Carl Zeiss Meditec carries the highest regional revenue exposure at 2% to 3% of sales, alongside energy costs near 3% of COGS. Siemens Healthineers disclosed Middle East revenues below 5% of sales and flagged a potential annualized adjusted EBIT impact of 2 to 4 percentage points from supply chain cost pressures before mitigations. Smith & Nephew reported approximately 1.5% exposure across all three risk categories, while Sonova's Middle East sales exposure exceeds 1%, including Israel.

RBC maintained Outperform ratings on Alcon, ConvaTec, and Siemens Healthineers, and expressed a preference for Sonova over a 12-month horizon. The bank remains cautious on Smith & Nephew, Philips, Coloplast, Carl Zeiss Meditec, Demant, GN, and Amplifon. Additionally, RBC flagged helium supply constraints as a concern for imaging-focused companies, though ongoing consumption responsibilities typically transfer to customers after initial MRI delivery.